Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies

Eur J Health Econ. 2018 Mar;19(2):267-275. doi: 10.1007/s10198-017-0882-x. Epub 2017 Mar 3.

Abstract

The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of and societal willingness to pay for health technologies, gains in quality of life and length of life are prima facie separate criteria that need not be put together in a single concept. A focus on costs per QALY can also be counterproductive. One reason is that the QALY does not capture well the value of interventions in patients with reduced potentials for health and thus different reference points. Another reason is a need to separate losses of length of life and losses of quality of life when it comes to judging the strength of moral claims on resources in patients of different ages. An alternative to the cost-per-QALY approach is outlined, consisting in the development of two bivariate value tables that may be used in combination to estimate maximum cost acceptance for given units of treatment-for instance a surgical procedure, or 1 year of medication-rather than for 'obtaining one QALY.' The approach is a follow-up of earlier work on 'cost value analysis.' It draws on work in the QALY field insofar as it uses health state values established in that field. But it does not use these values to weight life years and thus avoids devaluing gained life years in people with chronic illness or disability. Real tables of the kind proposed could be developed in deliberative processes among policy makers and serve as guidance for decision makers involved in health technology assessment and appraisal.

Keywords: Absolute shortfall; Cost value analysis; Graded willingness to pay; Proportional shortfall; QALY; Societal value.

MeSH terms

  • Cost-Benefit Analysis
  • Decision Making
  • Humans
  • Quality of Life
  • Quality-Adjusted Life Years*
  • Technology Assessment, Biomedical / economics*